Myasthenia Gravis

Myasthenia gravis (MG) is a rare chronic autoimmune disease of the neuromuscular junction characterized by a bimodal age distribution and complex interactions between genetic predisposition and environmental triggers. While historically considered a disease of the young, recent temporal trends indicate a significant rise in the incidence and prevalence of the condition among the elderly ^[2].

Incidence and Prevalence

The global epidemiology of MG is shifting, with an increasing burden in the very old (defined as age >65 years) ^[2]. In women, the onset age distribution frequently peaks within the reproductive age range, which complicates clinical management during pregnancy and the postpartum period ^[1]. In contrast, childhood-onset myasthenia gravis (CMG) remains rare, though its incidence is reportedly increasing annually in certain regions, such as China, where it accounts for 10.3% to 12.6% of new cases ^[17]D. CMG typically exhibits a single peak at ages 1–3 years ^[17]D.

Serological status also varies by clinical phenotype. In patients with ocular myasthenia gravis (OMG), approximately 45.9% are positive for acetylcholine receptor antibodies (AChR-Ab+), while the remainder are seronegative ^[8]. The presence of these antibodies in OMG is a known risk factor for progression to generalized myasthenia gravis (gMG) ^[8].

Demographic Distribution

MG exhibits a distinct sex-based predilection that varies by age of onset:

• Early-Onset MG: Predominantly affects women, particularly those in their 20s and 30s ^[1].
• Late-Onset MG (LOMG): Defined as onset after age 50 or 65, this group shows an increasing incidence, likely due to unknown environmental factors and improved diagnostic recognition in the elderly ^[2][10].
• Childhood-Onset MG: In large cohorts, the male-to-female ratio is approximately 1:1.4, with a median onset age of 5 years ^[17]D.

Risk Factors and Triggers

Metabolic and Lifestyle Factors

Obesity has emerged as a significant risk factor for the development of MG. A nationwide cohort study found that individuals with a BMI ≥ 30.0 (Obese Class II) have a significantly higher risk of newly diagnosed MG (HR 1.33) compared to those with a normal BMI ^[13]. This association is thought to be mediated by the pro-inflammatory environment induced by excess adipose tissue ^[13].

Pharmacological Triggers

Several medication classes are associated with the induction or exacerbation of MG:

• Statins : Multinational real-world data suggest a potential risk of new-onset MG following the initiation of statin therapy ^[15]C.
• Immune Checkpoint Inhibitors (ICIs): These anti-tumor agents can induce neurotoxicity as an immune-related adverse event (irAE). Patients with preexisting MG or thymoma are at particularly high risk for severe flares when treated with ICIs ^[18]D[21]D.

Infectious Triggers

Infections are the most common triggers for both the initial onset and subsequent exacerbations of MG. In childhood-onset cases, the common cold is the most prevalent trigger ^[17]D. More recently, COVID-19 and Long COVID have been identified as independent predictors of MG exacerbation ^[3][9]. Long COVID, in particular, serves as a risk factor for increased disease severity and mortality in MG patients ^[9].

Comorbidities and Associated Risks

Patients with MG have a higher prevalence of several comorbidities compared to the general population. Circulatory diseases, particularly hypertension (13–24%), are frequent before diagnosis ^[24]D. Post-diagnosis, patients often develop anemia and osteoporosis, likely secondary to long-term immunosuppressive therapy ^[24]D.

There is also a documented increase in the prevalence of extrathymic neoplasms in MG patients (HR 1.34) ^[11]. While thymectomy is a standard treatment for MG, its long-term impact on the risk of developing other cancers or autoimmune diseases remains a subject of clinical debate ^[23]D. Furthermore, Mendelian randomization studies suggest that MG may have a causal influence on the risk of neurodegenerative disorders, including Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) ^[7].

Risk Factor Summary Table

Myasthenia gravis (MG) is a prototypical autoimmune disorder of the neuromuscular junction characterized by fluctuating skeletal muscle weakness and pathological fatigability ^[33][36]D. The clinical hallmark is the worsening of symptoms following repetitive activity or towards the end of the day (diurnal variation), with partial or complete recovery after rest ^[36]D[47]D. While the disease course is often chronic, symptoms can progress over days to weeks during acute exacerbations, reaching a clinical nadir within 2 to 4 weeks in the setting of an impending crisis ^[30][41]C.

Presenting Symptoms

The initial presentation of MG is highly variable but most commonly involves the extraocular muscles. Approximately 50% of patients present with ocular symptoms alone, such as ptosis (drooping of the eyelids) or diplopia (double vision) ^[8][35]. These symptoms are often asymmetrical and shift from one eye to the other.

In generalized myasthenia gravis (gMG), weakness extends beyond the ocular muscles to involve bulbar, limb, and respiratory musculature ^[26][44]D. Bulbar involvement manifests as dysarthria (slurred speech), dysphagia (difficulty swallowing), and weakened mastication, which may cause the jaw to hang open ^[43]C[45]C. Limb weakness is typically proximal and symmetrical, affecting the shoulders and hips more than distal muscles ^[38]D. Respiratory involvement is the most critical feature, as it can lead to hypercapnic respiratory failure ^[43]C[46]D.

Neurological Examination Findings

The neurological examination must focus on demonstrating fatigability, as static strength may be normal during initial testing.

• Cranial Nerve Examination: Assess for ptosis by asking the patient to maintain an upward gaze for 60 seconds; a gradual drooping of the lid is a positive finding. Diplopia may be elicited by sustained lateral gaze. Bulbar strength is evaluated by assessing the clarity of speech during prolonged counting and the strength of the gag reflex ^[43]C.
• Motor Examination: Proximal limb strength should be tested repeatedly. For example, ask the patient to perform repeated chair rises or hold their arms in abduction for 2 minutes.
• Reflexes and Sensation: Deep tendon reflexes are typically preserved, and sensory examination is normal, which helps distinguish MG from Lambert-Eaton Myasthenic Syndrome or Guillain-Barré Syndrome ^[33].
• Autonomic Function: Autonomic instability is not a feature of primary MG; its presence should prompt investigation for overlap syndromes, such as PD-1 inhibitor-associated myocarditis ^[45]C.

Phenotypic Variants

MG is classified into several distinct phenotypes based on antibody status and clinical distribution. While acetylcholine receptor antibodies (AChR-Ab) are the most common, muscle-specific kinase (MuSK) and double-seronegative (dSNMG) variants present unique challenges ^[33][44]D.

Red Flags

Clinicians must remain vigilant for signs of an impending myasthenic crisis (MC), a life-threatening state of respiratory failure ^[41]C[46]D.

Step-by-Step Assessment for Impending Crisis:

1. Monitor Respiratory Mechanics: Perform bedside pulmonary function testing. An FVC < 15 mL/kg or a Maximal Inspiratory Pressure (MIP) < -30 cmH2O are critical thresholds for considering elective intubation ^[41]C[46]D.
2. Evaluate Bulbar Competency: Assess for the "curtain sign" (severe ptosis) and the inability to clear secretions, which increases the risk of aspiration ^[43]C.
3. Identify Triggers: Screen for infections, recent medication changes (e.g., starting erenumab or PD-1 inhibitors), or surgical stressors ^[39]C[45]C.

Atypical Presentations

MuSK-positive MG often presents atypically, sometimes manifesting solely as isolated respiratory failure without significant ocular or limb involvement ^[43]C. This can lead to significant diagnostic delays. Furthermore, drug-induced MG-like syndromes have been reported with novel therapies; for instance, the CGRP antagonist erenumab has been associated with late-onset ocular symptoms ^[39]C. Another critical atypical presentation is the MMM Syndrome (Myasthenia, Myocarditis, and Myositis) associated with immune checkpoint inhibitors, which carries a high mortality rate and requires rapid rescue therapy with agents like efgartigimod 10 mg/kg ^[45]C.

The management of myasthenia gravis (MG) exacerbations and myasthenic crisis (MC) requires a high-intensity, multi-disciplinary approach focused on rapid immunomodulation and aggressive respiratory support. Myasthenic crisis, defined as life-threatening respiratory failure requiring mechanical ventilation, affects 10% to 20% of MG patients during their disease course ^[55][63]D. Early identification of an impending myasthenic crisis (IMC)—characterized by rapid progression of bulbar or respiratory symptoms within ≤2 weeks—is essential to prevent progression to full crisis and intubation ^[49][57].

Step 1: Initial Assessment and Severity Classification

Clinicians must immediately classify the patient's status to determine the appropriate level of care (ICU vs. specialized neurology ward). Severity is assessed using the Myasthenia Gravis Foundation of America (MGFA) classification and the Quantitative Myasthenia Gravis (QMG) score ^[49][56]C.

Criteria for ICU Admission or High-Dependency Care:

• MGFA Grade IVb (severe bulbar/respiratory weakness) ^[49].
• QMG Bulbar Subscore of 3 or Respiratory Subscore of 2 ^[49].
• Combined Bulbar-Respiratory Subscore ≥4 ^[49].
• Evidence of hypercapnic respiratory failure (e.g., coma or altered mental status) ^[43]C.

Step 2: Rapid Immunomodulation

Once IMC or MC is identified, rapid-acting therapies must be initiated to reduce the concentration of pathogenic antibodies at the neuromuscular junction.

• Efgartigimod (FcRn Antagonist): Administer 10 mg/kg IV weekly for 4 weeks ^[49][30]. Efgartigimod is increasingly preferred for IMC because it demonstrates significantly greater improvements in MG-ADL and QMG scores from weeks 2 to 4 compared to IVIg (Level 1b) ^[57]. It has also shown efficacy in perioperative management for patients with thymoma to prevent postoperative crisis ^[62]C.
• Intravenous Immunoglobulin (IVIg): Standard dosing is 2 g/kg IV divided over 2 to 5 days ^[60]. While widely used, its efficacy in generalized MG remains subject to some uncertainty in meta-analyses compared to newer biologics ^[60].
• Plasmapheresis (PLEX): Typically involves 5 to 7 exchanges over 10 to 14 days ^[52]. PLEX is often more cost-effective than IVIg in many healthcare settings, though it requires specialized vascular access ^[52].

Step 3: Respiratory Support and Airway Protection

Respiratory failure in MG is often hypercapnic due to diaphragmatic and intercostal muscle fatigue ^[43]C.

1. Non-Invasive Ventilation (NIV): May be attempted in patients with mild respiratory distress, but clinicians must have a low threshold for intubation if bulbar weakness is severe, as NIV does not protect against aspiration ^[58]D.
2. Invasive Mechanical Ventilation : Indicated if the patient cannot maintain a patent airway due to severe dysphagia (bulbar weakness) or if vital capacity falls below 15-20 mL/kg ^[55].
3. Dysphagia Management: Patients with a QMG bulbar subscore ≥2 should be kept NPO (nothing by mouth) to prevent aspiration pneumonia ^[58]D.

Step 4: Monitoring and Complication Prevention

Continuous monitoring is required to detect systemic complications triggered by the physiological stress of a crisis.

• Cardiac Monitoring: Patients are at risk for Takotsubo cardiomyopathy (TTC), a stress-induced left ventricular dysfunction that can occur during MG exacerbations ^[50]. Non-apical TTC subtypes may be more frequent in certain MG populations ^[50].
• Antibody Titers: Dynamic monitoring of anti-AChR antibody levels can help predict the risk of further exacerbations after achieving minimal symptom expression (MSE) ^[53].
• Thromboprophylaxis: Standard ICU protocols for venous thromboembolism (VTE) prevention should be followed, as immobility during crisis increases risk.

Step 5: Resolution and Transition to Maintenance

Resolution is defined by the stabilization of respiratory status and improvement in MG-ADL scores by ≥2 points ^[53].

• Weaning: Gradually transition from mechanical ventilation as bulbar strength returns.
• Maintenance: Initiate or escalate long-term immunosuppression (e.g., corticosteroids or steroid-sparing agents) to maintain pharmacologic remission or MSE ^[54][56]C.
• Follow-up: Post-crisis patients require close monitoring for at least 12 months, as in-hospital mortality is approximately 5.05%, and all-cause mortality remains a risk during the first year ^[55].

Treatment Failure Protocol

If first-line rapid therapies (IVIg, PLEX, or Efgartigimod) fail to produce clinical improvement within 1-2 weeks, or if the patient is refractory:

1. C5 Inhibitors: Administer Eculizumab (emergency dosing) or Ravulizumab ^[41]C[61]C.
2. Ravulizumab: Has shown success in treating myasthenic crises associated with invasive thymoma (Masaoka stage IVa) that were refractory to conventional therapy ^[61]C.
3. Eculizumab: Can be used as emergency therapy in AChR-Ab+ patients with impending or manifest MC, showing rapid onset of effect in acute episodes ^[41]C.

What NOT to Do

• Do NOT delay intubation in a patient with rapidly declining vital capacity or severe bulbar weakness, even if oxygen saturation is currently normal; MG crisis is a failure of ventilation, not necessarily oxygenation ^[43]C[55].
• Do NOT use Magnesium Sulfate or certain aminoglycosides, as these can precipitously worsen neuromuscular blockade ^[56]C.
• Do NOT rely solely on NIV in patients with profound dysphagia, as the risk of silent aspiration is high ^[58]D.

The prognosis of myasthenia gravis (MG) has been fundamentally transformed by the advent of modern immunomodulatory therapies and refined surgical techniques. Once associated with high mortality, MG is now considered a manageable chronic condition for the majority of patients. However, the clinical trajectory remains highly variable, influenced by the timing of intervention, thymic pathology, and the presence of specific autoantibodies ^[28][54][69].

Overview of Clinical Trajectory and Mortality

In the modern era, the mortality 3-7% is largely confined to patients experiencing myasthenic crisis (MC) or those with significant comorbidities ^[55]. A multicenter prospective study found that in-hospital mortality for MC is approximately 5.05%, with all-cause mortality reaching 6.86% at one year post-crisis ^[55]. Despite the severity of these episodes, functional recovery is common; approximately 80% walk independently at 6 months following an acute exacerbation, provided they receive intensive care and rapid-acting therapies such as efgartigimod (10 mg/kg) or intravenous immunoglobulin (IVIg 2 g/kg) ^[49][55].

Recovery is often characterized by a fluctuating course. Patients achieving Minimal Symptom Expression (MSE) remain at risk for exacerbations, defined as an increase of ≥ 2 points in the MG Activities of Daily Living (MG-ADL) score ^[53]. Dynamic monitoring of anti-acetylcholine receptor (AChR) antibody levels is a critical prognostic tool; rising titers often precede clinical worsening, allowing for preemptive therapeutic adjustments ^[53][68].

Predictors of Clinical Outcome

Prognosis is heavily dependent on the timing of treatment escalation. The "Early Intensified Treatment" (EIT) strategy—initiating targeted add-on therapies like efgartigimod or C5 inhibitors within 24 months of diagnosis—is associated with superior clinical outcomes compared to late intensified treatment (LIT) ^[28]. This is likely due to intervention occurring before permanent structural damage at the neuromuscular junction or immunological consolidation takes place ^[28].

Impact of Surgical and Medical Interventions

Thymectomy remains a cornerstone of long-term management , particularly in AChR-antibody-positive patients. Long-term follow-up (up to 5 years) indicates that a significant proportion of patients achieve complete stable remission (CSR) or pharmacologic remission ^[54]. The clinical benefit of thymectomy correlates with a reduction in AChR-specific IgG titers ^[68]. While both robotic-assisted (RATS) and video-assisted (VATS) thoracoscopic surgery provide comparable long-term outcomes, RATS may offer technical advantages in complex dissections ^[72].

Emerging therapies like BCMA-directed mRNA CAR T-cell therapy (Descartes-08) have shown the potential for sustained clinical improvement (≥5-point improvement in MG Composite score) lasting up to 12 months after a single treatment cycle, suggesting a possible shift toward long-term drug-free remission ^[67].

Long-term Sequelae and Quality of Life

Despite achieving low disease activity, many patients suffer from persistent "invisible" symptoms that significantly impair quality of life (MG-QOL15).

• Fatigue and Sleep: Sleep disorders are highly prevalent and contribute to chronic fatigue ^[4]. These are often under-recognized but are primary drivers of reduced daily functioning ^[4].
• Psychosocial Impact: Anxiety and depression are common, necessitating holistic approaches. Integrated programs combining adapted physical activity (APA) and art therapy have been proposed to address these psychosocial burdens ^[71].
• Rare Complications: Patients with thymoma must be monitored for rare but severe paraneoplastic syndromes, such as thymoma-related aplastic anemia, which can occur even post-thymectomy and carries a high mortality rate ^[73].

Protocol for Long-term Monitoring

To optimize prognosis, clinicians should follow a structured monitoring protocol to detect impending exacerbations and manage treatment side effects.

1. Step 1: Baseline Assessment: Establish baseline MG-ADL, QMG, and MG-QOL15 scores during the stable phase.
2. Step 2: Periodic Serology: Monitor AChR-antibody titers every 6–12 months, or more frequently if symptoms fluctuate ^[53].
3. Step 3: Symptom Surveillance: Evaluate for "minimal manifestations" (MM) status. If the patient exceeds MSE thresholds, consider early escalation to FcRn antagonists (e.g., efgartigimod 10 mg/kg) rather than relying solely on pyridostigmine (60 mg every 4 hours) ^[28][65].
4. Step 4: Comorbidity Management: Screen for sleep apnea and osteoporosis (if on chronic steroids) to mitigate long-term treatment sequelae ^[4].

Management of myasthenia gravis (MG) requires significant tailoring based on the patient's life stage, physiological state, and comorbid profile. The therapeutic window for immunosuppression often narrows in the very young and the elderly, while pregnancy introduces complex considerations regarding teratogenicity and neonatal antibody transfer ^[1][76]D.

Pregnancy and the Postpartum Period

MG frequently affects women of childbearing age, with a peak incidence in the second and third decades ^[1]. Pregnancy does not have a uniform effect on MG; approximately one-third of patients improve, one-third remain stable, and one-third experience exacerbations, particularly during the first trimester and the immediate postpartum period ^[1][76]D.

Management Protocol for Pregnancy:

1. Pre-conception Counseling: Transition patients off teratogenic medications. Mycophenolate mofetil and methotrexate must be discontinued at least 3 months prior to conception due to high risks of fetal malformation ^[76]D.
2. Symptomatic Control: Pyridostigmine (standard dose 60 mg every 4–6 hours) remains the first-line symptomatic treatment and does not cross the placenta in significant amounts ^[65][76]D.
3. Immunosuppression: If steroids are required, prednisone is preferred as it is largely metabolized by placental enzymes. Azathioprine (2–3 mg/kg/day) is considered the safest non-steroidal immunosuppressant during pregnancy ^[37]D[76]D.
4. Crisis Prevention: For impending crisis or rapid worsening, IVIG (2 g/kg over 2–5 days) or efgartigimod (10 mg/kg weekly) may be used, though data for efgartigimod in pregnancy is still emerging ^[49][76]D.
5. Delivery Planning: Spontaneous vaginal delivery is preferred. Magnesium sulfate is strictly contraindicated for preeclampsia in MG patients as it can precipitate a fatal myasthenic crisis by blocking neuromuscular transmission ^[76]D.

Transient Neonatal Myasthenia Gravis: Approximately 10–20% of neonates born to MG-positive mothers experience transient weakness due to the transplacental transfer of maternal AChR antibodies ^[76]D. Symptoms typically appear within the first 48 hours and may require temporary anticholinesterase treatment or respiratory support.

Juvenile Myasthenia Gravis (JMG)

Juvenile MG (onset before age 18) presents unique challenges regarding long-term immunosuppression and developmental impact. While the clinical features often mirror adult-onset MG, JMG has a higher rate of spontaneous remission in prepubertal patients ^[27].

Treatment Modifications:

• First-line: Pyridostigmine remains the backbone of therapy. If symptoms persist, low-dose corticosteroids are initiated.
• Steroid-Sparing Agents: In refractory cases, azathioprine or cyclosporine are utilized. A meta-analysis of JMG treatments indicates that early intervention with immunomodulators can improve long-term outcomes and reduce the need for high-dose steroids ^[27].
• Thymectomy: Often considered earlier in JMG (especially in generalized AChR-positive cases) to facilitate long-term remission and avoid the growth-stunting effects of chronic steroid use ^[27].

Elderly and Late-Onset Myasthenia Gravis

Late-onset MG (LOMG), defined as onset after age 65, is becoming increasingly common ^[2]. Diagnosis in the elderly is frequently delayed because symptoms like ptosis, fatigue, and dyspnea are often misattributed to normal aging, cerebrovascular disease, or cardiovascular comorbidities ^[2].

Clinical Considerations:

• Diagnostic Pitfalls: Elderly patients have a higher prevalence of comorbid autoimmune diseases and may present with "double trouble" scenarios, such as the co-occurrence of MG and facioscapulohumeral muscular dystrophy ^[74]C[77].
• Treatment Risks: The elderly are more susceptible to steroid-induced side effects, including osteoporosis, hyperglycemia, and hypertension . Consequently, there is a lower threshold to initiate non-steroidal agents or targeted therapies like efgartigimod (10 mg/kg), which has shown consistent efficacy across age groups with a favorable safety profile ^[31][49].
• Drug Interactions: Polypharmacy in the elderly increases the risk of drug-induced MG exacerbations (e.g., from beta-blockers or certain antibiotics ) ^[2].

Immunocompromised and Refractory Populations

Patients with refractory generalized MG (gMG) who fail conventional therapies represent a high-risk group. Recent advances have introduced targeted biologicals and cellular therapies.

• Targeted Add-on Therapy: Initiation of complement C5 inhibitors (e.g., eculizumab) or FcRn antagonists (efgartigimod) within 24 months of diagnosis (Early Intensified Treatment) is associated with better clinical outcomes compared to late escalation ^[28].
• CAR-T Therapy: For highly refractory cases, autologous CD19/BCMA CAR-T cell therapy is being investigated. This approach aims to "reset" the immune system by depleting the B-cell and plasma cell compartments responsible for pathogenic antibody production ^[34].
• Checkpoint Inhibitor-Induced MG: Patients receiving immune checkpoint inhibitors (ICIs) for cancer, such as pembrolizumab, are at risk for de novo or exacerbated MG ^[66][70]. These cases are often severe and require immediate cessation of the ICI and aggressive treatment with steroids and IVIG ^[70].

The management of myasthenia gravis (MG) is guided by several international consensus statements and evidence-based practice parameters. These guidelines emphasize a tailored approach based on the clinical subtype (ocular vs. generalized), antibody status (AChR, MuSK, or LRP4), and the presence of thymic pathology ^[83][84]. Recent updates have significantly shifted the standard of care, particularly regarding the role of surgical intervention in nonthymomatous disease ^[83].

Major Consensus Guidelines

American Academy of Neurology (AAN) 2020 Update

The 2020 AAN practice advisory represents a pivotal shift in MG management, specifically addressing the role of thymectomy . Based on Class I evidence, the guideline recommends thymectomy for patients aged 18 to 65 years with nonthymomatous acetylcholine receptor antibody-positive (AChR ab+) generalized MG ^[83]. The rationale is that surgical intervention, when combined with oral prednisone, increases the probability of attaining minimal manifestation status (MMS) and reduces the required dose of corticosteroids compared to medical therapy alone ^[83].

European Federation of Neurological Societies (EFNS)

The EFNS guidelines provide a comprehensive framework for the treatment of autoimmune neuromuscular transmission disorders ^[84][85]. These guidelines establish a hierarchy of treatment, beginning with acetylcholinesterase inhibitors and escalating to immunosuppression or plasma exchange (PLEX) based on severity ^[84]. A key clinical pearl from the EFNS is the recommendation for caution when using anticholinesterase drugs in patients with MuSK antibodies, as these patients may be less responsive or more prone to cholinergic side effects ^[84].

National Comprehensive Cancer Network (NCCN) 2025

For patients with MG secondary to thymoma , the NCCN Guidelines for Thymomas and Thymic Carcinomas (Version 2.2025) emphasize a multidisciplinary approach ^[80]. Because thymoma-associated MG is a paraneoplastic syndrome, management must balance the treatment of the underlying malignancy with the stabilization of neuromuscular symptoms ^[80][86].

Protocol for Thymectomy Decision-Making

Based on the AAN 2020 update, clinicians should follow this protocol for evaluating surgical candidacy in MG ^[83]:

1. Step 1: Confirm Diagnosis: Verify AChR antibody positivity and generalized clinical features (not purely ocular).
2. Step 2: Age Assessment: Identify patients between 18 and 65 years of age.
3. Step 3: Imaging: Perform chest CT or MRI to screen for thymoma; if present, thymectomy is indicated regardless of MG severity ^[80][86].
4. Step 4: Clinical Optimization: Stabilize the patient with medical therapy (e.g., pyridostigmine , steroids) to ensure they are safe for anesthesia and surgery.
5. Step 5: Surgical Referral: Proceed with thymectomy to improve long-term clinical outcomes and reduce steroid burden ^[83].

Guidelines for Acute and Short-Term Management

In cases of myasthenic crisis or severe exacerbation, rapid-acting therapies are prioritized. The EFNS and Canadian guidelines provide specific evidence levels for the use of intravenous immunoglobulin (IVIG) ^[87][88].

• IVIG Protocol: For acute exacerbations, IVIG is typically administered at 0.4 g/kg/day for 5 days or 1 g/kg/day for 2 days ^[87]. It is recommended as a Level A treatment for short-term management of severe MG ^[87].
• Plasma Exchange (PLEX): Recommended as a Level B intervention for inducing rapid remission in severe cases or as a preoperative bridge to ensure respiratory stability during thymectomy ^[84][85].

Screening and Differential Diagnosis Guidelines

Guidelines for paraneoplastic screening recommend that all patients with a new diagnosis of MG undergo chest imaging (CT or MRI) to detect thymoma ^[86]. This is critical because the tumor directly affects the prognosis and treatment strategy ^[80]. Furthermore, clinicians must distinguish MG from other neuromuscular disorders. For instance, the 2021 CDC/MMWR guidelines for botulism highlight that while both conditions present with cranial nerve palsies and descending paralysis, botulism is characterized by a more rapid progression and specific exposure history (e.g., foodborne or wound) ^[79].

Clinical Prediction and Monitoring Tools

While specific calculators are often proprietary or institution-specific, the guidelines emphasize the use of standardized scales to monitor treatment response:

• MG Foundation of America (MGFA) Clinical Classification: Used to grade the severity of the disease.
• Minimal Manifestation Status (MMS): The primary goal of therapy, defined as the patient having no symptoms or functional limitations from MG, though they may have some mild weakness on formal muscle testing ^[83].

Patient Resources

Patients and caregivers can access high-quality information through the following resources:

• Myasthenia Gravis Foundation of America (MGFA): Provides patient education, support groups, and clinical trial information.
• NCCN Patient Guidelines: Specific resources for those dealing with thymoma-associated MG ^[80].
• AAN Patient Portal: Offers summaries of the latest practice advisories in lay language ^[83].